Karyopharm EVP reports PSU vesting; automated sale covers taxes
Rhea-AI Filing Summary
Stuart Poulton, EVP and Chief Development Officer of Karyopharm Therapeutics (KPTI), reported the vesting of 888 performance-based restricted stock units (PSUs) on 09/12/2025 after the company certified completion of enrollment in its Phase 3 SENTRY trial. Each PSU converts to one share, increasing his beneficial ownership to 28,111 shares. On 09/15/2025 he executed an automatic, broker-assisted sale of 401 shares at $6.43 to cover withholding taxes, leaving 27,710 shares beneficially owned. The PSUs were originally granted in February 2023 and vested upon certification by the Compensation Committee. The Form 4 was signed by an attorney-in-fact on 09/16/2025.
Positive
- Achievement of a Phase 3 clinical milestone (complete enrollment in the SENTRY trial) certified by the Compensation Committee, triggering PSU vesting
- Transparent disclosure of an automatic, broker-assisted sale to cover tax withholding rather than a discretionary insider trade
Negative
- None.
Insights
TL;DR: Vesting tied to a Phase 3 enrollment milestone signals clinical progress; transaction size is small relative to total float.
The reported vesting of 888 PSUs reflects achievement of a material clinical milestone for the SENTRY Phase 3 trial, which is directly relevant to Karyopharm's development program. While the dollar value realized by the reporting person is modest and the subsequent sale of 401 shares was an automated tax-withholding event, the certification by the Compensation Committee confirms a company-level operational achievement that could influence clinical timelines and investor sentiment. This disclosure is informational for modeling milestone-driven equity dilution and timing of potential future share releases tied to performance awards.
TL;DR: Disclosure appears routine and compliant; the sale was non-discretionary under a pre-established plan.
The Form 4 documents standard insider reporting: earned PSUs certified by the Compensation Committee and an automatic broker-assisted sale to satisfy tax withholding. Filing by attorney-in-fact is properly indicated. There is no sign of discretionary trading or unusual timing; governance controls (compensation committee certification and durable sale instructions) are evident. The filing raises no immediate compliance concerns based on the information provided.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 401 | $6.43 | $3K |
| Grant/Award | Common Stock | 888 | $0.00 | $0.00 |
Footnotes (2)
- F1. Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2023 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 SENTRY trial, as certified by the issuer's Compensation Committee on September 12, 2025. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on September 12, 2025.
- F2. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.
AI-generated analysis. How Rhea-AI works. Not financial advice.
